Effects of clofibrate and a fat-modified diet on serum lipids
- PMID: 164312
- DOI: 10.1002/cpt1975172171
Effects of clofibrate and a fat-modified diet on serum lipids
Abstract
The combined effect of clofibrate and a fat-modified diet was determined in 17 hyperlipidemic patients: 7 type IIA, 7 type IV, 2 type VI(IIB), and 1 type III. Control serum lipid levels and lipoprotein patterns and their alteration with a fat-modified diet had been determined previously 1/2 to 2 years for 3 patients, and 6 to 10 years for 14 patients. Two grams of clofibrate a day (0.5 gm four times daily) was taken along with the fat-modified diet for 2 to 6 months by 5 patients and for 2 years by 13 patients. The effect of clofibrate and a fat-controlled diet was also determined in 10 normolipidemic men who were subjects of an 18-day test in which the polyunsaturated fat diet was quantitatively prepared and eaten along with 2 gm clofibrate a day (0.5 gm four times daily). The effect of clofibrate on serum cholesterol levels was a further mean reduction in type IIA patients by 19 %, in type III by 23%, in type IV by 12%, in type VI by 7%, and in normolipidemic subjects by 8%. The extent of the additional serum cholesterol reduction with clofibrate in individual hyperlipidemic patients varied from +10% to minus 44% and was not related directly to the type of hyperlipidemia. The extent of reduction appeared related directly to the level of minus S 40-70 (similar to Sf 12-20) lipoprotein fraction in the control serum sample. Serum triglyceride levels were unaffected in type IIA and normolipidemic subjects. Serum triglyceride levels did not change consistently in the 2 type VI patients, rising by 11% in 1 and dropping by 31% in the other. Serum triglyceride levels were significantly (p = 0.001) and consistently reduced by 39% only in type IV patients.
Similar articles
-
Effect of vitamin E on serum cholesterol and triglycerides in hyperlipidemic patients treated with diet and clofibrate.Am J Clin Nutr. 1978 Jan;31(1):100-5. doi: 10.1093/ajcn/31.1.100. Am J Clin Nutr. 1978. PMID: 202160 Clinical Trial.
-
[Effect of a clofibrate-inositol nicotinate combination on lipids and lipoproteins in primary hyperlipoproteinemia of types IIa, IV and V].Arzneimittelforschung. 1983;33(5):776-9. Arzneimittelforschung. 1983. PMID: 6683558 German.
-
Polyunsaturated meat and dairy products in fat-modified food patterns for hyperlipidemia.J Am Diet Assoc. 1976 Sep;69(3):235-42. J Am Diet Assoc. 1976. PMID: 181413
-
Clofibrate and related compounds in hyperlipoproteinaemia. A review.Postgrad Med J. 1975;51(8):suppl 66-71. Postgrad Med J. 1975. PMID: 215983 Review. No abstract available.
-
Dyslipidemias in patients with diabetes mellitus: classification and risks and benefits of therapy.Pharmacotherapy. 1995 May-Jun;15(3):317-37. Pharmacotherapy. 1995. PMID: 7667166 Review.
Cited by
-
[Effect of clofibrate on lipoprotein-lipids in patients with type IV hyperlipoproteinaemia (author's transl)].Klin Wochenschr. 1977 Aug 15;55(16):791-4. doi: 10.1007/BF01651267. Klin Wochenschr. 1977. PMID: 198601 German.
-
Usefulness of probucol in treating primary hypercholesterolemia.Can Med Assoc J. 1980 Oct 18;123(8):754-7. Can Med Assoc J. 1980. PMID: 7448680 Free PMC article. Clinical Trial.
-
G Protein-Coupled Receptors in Taste Physiology and Pharmacology.Front Pharmacol. 2020 Nov 30;11:587664. doi: 10.3389/fphar.2020.587664. eCollection 2020. Front Pharmacol. 2020. PMID: 33390961 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources